MoneyWorks4Me

Zydus Lifesciences informs about press release

06 Dec 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated December 6, 2023 titled ‘Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1133.60 -16.40 (-1.43%)
09-Sep-2026 13:09 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1873.80
Dr. Reddys Labs. 1145.85
Cipla 1371.50
Lupin 2105.95
Zydus Lifesciences 1133.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: